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estimated. Model variables included insurer’s type, age, gender,
charlson comorbidity index, year. Odd ratios(OR) and 95%
conﬁdence intervals(CI) were used to investigate the impact of
medicaid expansion on PH trend. The PHwas deﬁned as a class of
admission believed to be preventable in most cases by standard
ambulatory health care before admission. The marker admissions
were determined such as appendicitis and gastrointestinal
obstruction, remaining relatively constant across populations.
RESULTS: Among newly enrolled 140,366 medicaid population,
62.1% were female, mean age was 52 years old. These percentage
of female and mean age among 280,301 NHI population were
53.1% and 39 years old, respectively. The biennial ratio of PH
relative to marker admission in medicaid population increased
after eligibility expansion, from an average of 6.05 to
9.04(OR = 1.50). This rise was small compared with the NHI
populations, who experienced from 1.96 to 3.22(OR = 1.64).
After adjusting for confounding variables, the OR for after med-
icaid expansion among medicaid population and NHI population
were 1.48(95% CI = 1.29–1.69) and 1.71(95% CI = 1.53–1.91),
respectively. CONCLUSIONS: Current ﬁndings suggest that the
medicaid PH trend was less likely to rise than NHI PH trend after
implementing medicaid expansion.
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OBJECTIVES: The purpose of this study is to examine the
impact of visual acuity (VA) on bilateral neovascular age-related
macular degeneration (nvAMD) patients’ general quality of life
(QOL). Instead of the traditional correlation/linear regression
analysis, a novel approach using PROBIT regression on cumula-
tive QOL rates was employed. METHODS: Data from a
cross-sectional, multi-country (France, Germany, Spain, UK and
Canada) burden of nvAMD was examined (n = 401 nvAMD
patients). As part of the telephone interview, patients completed
EQ-5D as the assessment of general quality of life (QOL). Asso-
ciations between VA and EQ-5D were examined using traditional
Pearson correlation, analysis of variance (ANOVA) test of
EQ-5D score as a function of VA level (normal, mild, moderate,
severe, and near blindness), and PROBIT regression. In the
PROBIT regression, the decimal VA was ordinalized into catego-
ries centered at 0.02, 0.04, 0.06, etc., and cumulative QOL rates
were calculated at each of these levels. RESULTS: Pearson cor-
relation and one-way analysis of variance tests showed no sig-
niﬁcant association between VA and EQ-5D. From the PROBIT
regression, the inﬂection points were determined and the mean
and standard deviation of the underlying normal distribution
were estimated. The inﬂection points identify the VA levels at
which association between QOL and VA may be expected and at
what level no association would occur. The mean and SD dem-
onstrate where the relationship was linear. While the Pearson
correlation showed a 0.01 correlation coefﬁcient between EQ-5D
and VA, PROBIT regression showed a 0.89 correlation coefﬁ-
cient, with the association being linear between VA range of 0.02
and 0.40. CONCLUSIONS: The association of VA levels and
EQ-5D is affected by many extraneous variables that make it
difﬁcult to identify the strength of the association. The use of
PROBIT regression gives researchers an important methodologi-
cal tool to strengthen their understanding of such associations.
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OBJECTIVES: When a budget impact analysis is performed for
the introduction of a new drug, the diffusion of the drug needs to
be forecasted. Such forecast should be as evidence-based as pos-
sible if it is to be useful for health care decision makers. We
assessed the usefulness of several models for predicting the diffu-
sion of new drugs on the Dutch market. METHODS: Several
diffusion models were assessed, and the most useful in the context
of a new drug entering the market was selected. Next, historical
diffusion was analysed based on Farminform and IMS data. This
data provides sales (volume) at the level of the active substance for
the total Dutch market each month. Data was available from
January 1993 until October 2006. We included data on 22
products divided over 6 ATC 2 categories (ATC = Anatomical
Therapeutic Chemical). RESULTS: We found that the Hahn
model is most applicable for new drugs. The Hahn model was
capable of describing diffusion retrospectively of the 22 drugs
studied. The results provide insight in the diffusion pattern which
can be used to forecast diffusion of new interventions. Based on
these empirically derived descriptors of diffusion some ﬁndings
were: The biggest growth (relative to the previous period) of a
product is achieved between roughly 12 and 36 months; No
products are observed with a market (ATC2) penetration of more
than 45%; In less than a ﬁfth of the introductions, a market share
ofmore than 20%at theATC2 level is achievedwithin 60months;
In less than a tenth of the introductions, a market share of more
than 35% at the ATC 2 level is achieved within 60 months.
CONCLUSIONS: The assumptions about market diffusions cur-
rently made in budget impact analyses can be greatly improved if
formal models are used to predict diffusion.
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OBJECTIVES: Most international pharmacoeconomic guide-
lines advise not to include future unrelated medical costs in
economic evaluations. Recently, arguments in favor of inclusion
of such costs are gaining support in health economic literature.
However, correct estimations of these costs do not yet exist. This
paper describes the methodology with which we developed a
toolkit to adjust incremental cost-effectiveness ratios (ICER) for
future unrelated medical costs, and presents an application of the
toolkit by adjusting the ICER of universal hepatitis B vaccination
of newborns. METHODS: We deﬁned three variables that
predict individual health care expenditure best: age, sex and time
to death. However, the relation between health care expenditure
and these three variables depends on the lethality of diseases and
on health care setting. For the development of the toolkit, differ-
ent cross-sectional and longitudinal databases were used. First,
the 2003 Dutch Cost of Illness study has been employed. Fur-
thermore, insurance claims data and longitudinal record linkage
data were used. This allowed us to estimate how the relation
between time to death and health care costs is altered if costs of
related diseases are excluded. To apply the toolkit, survivor
curves for the intervention and control groups are needed. For
hepatitis B vaccination of newborns, future unrelated medical
costs (i.e. all costs not related to hepatitis B infection and
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